Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
Technology supplier developing surface chemistry for biosensors, gold nanoparticles, and biochips to enhance medical diagnostic sensitivity.
Kimialys is a Paris-Saclay, France-based organization that develops patented K-One® surface chemistry technology for biosensors, specifically gold nanoparticles and biochips used in rapid diagnostic tests and molecular biology applications. Their innovative surface treatment enhances detection sensitivity by 3-10 times and improves specificity in complex biological samples. Operating as both a technology supplier and service provider, Kimialys supports diagnostic developers and clinical partners in areas like infectious disease diagnostics and immunotherapy monitoring. The company has secured nearly €1 million in private funding and an additional €1.3 million in non-dilutive financing from Bpifrance, supporting its 21-50 employees. Kimialys was founded in October 2020 by Dr. Claude Noguès and Cyril Gilbert. Reported scale details include 21-50 employees, secured nearly €1 million in private funding plus €1.3 million in non-dilutive financing from Bpifrance for co-development projects.
Kimialys has raised $4.2M across 1 funding round.
Kimialys has raised $4.2M in total across 1 funding round.
Kimialys has raised $4.2M across 1 funding round. Most recently, it raised $4.2M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 23, 2025 | $4.2M Series A | Turenne Santé | Angels Sant, Badge, Evolem, Octalfa, Odiem Capital | Announced |
Kimialys has raised $4.2M in total across 1 funding round.
Kimialys's investors include Turenne Santé, Angels Sant, BADGE, Evolem, Octalfa, Odiem Capital.